Search Results
Search for other papers by Tobias Hofving in
Google Scholar
PubMed
Search for other papers by Yvonne Arvidsson in
Google Scholar
PubMed
Search for other papers by Bilal Almobarak in
Google Scholar
PubMed
Search for other papers by Linda Inge in
Google Scholar
PubMed
Search for other papers by Roswitha Pfragner in
Google Scholar
PubMed
Search for other papers by Marta Persson in
Google Scholar
PubMed
Search for other papers by Göran Stenman in
Google Scholar
PubMed
Search for other papers by Erik Kristiansson in
Google Scholar
PubMed
Search for other papers by Viktor Johanson in
Google Scholar
PubMed
Search for other papers by Ola Nilsson in
Google Scholar
PubMed
gastroenteropancreatic neuroendocrine tumors. Journal of the National Cancer Institute 100 1282 – 1289 . ( https://doi.org/10.1093/jnci/djn275 ) 18780869 10.1093/jnci/djn275 Perren A Komminoth P Saremaslani P Matter C Feurer S Lees JA Heitz PU Eng C 2000
Search for other papers by Matti L Gild in
Google Scholar
PubMed
Search for other papers by Iñigo Landa in
Google Scholar
PubMed
Human Oncology and Pathogenesis Program, Department of Medicine, Department of Pathology
Search for other papers by Mabel Ryder in
Google Scholar
PubMed
Search for other papers by Ronald A Ghossein in
Google Scholar
PubMed
Search for other papers by Jeffrey A Knauf in
Google Scholar
PubMed
Human Oncology and Pathogenesis Program, Department of Medicine, Department of Pathology
Search for other papers by James A Fagin in
Google Scholar
PubMed
Inhibitors of RET, a tyrosine kinase receptor encoded by a gene that is frequently mutated in medullary thyroid cancer, have emerged as promising novel therapies for the disease. Rapalogs and other mammalian target of rapamycin (mTOR) inhibitors are effective agents in patients with gastroenteropancreatic neuroendocrine tumors, which share lineage properties with medullary thyroid carcinomas. The objective of this study was to investigate the contribution of mTOR activity to RET-induced signaling and cell growth and to establish whether growth suppression is enhanced by co-targeting RET and mTOR kinase activities. Treatment of the RET mutant cell lines TT, TPC-1, and MZ-CRC-1 with AST487, a RET kinase inhibitor, suppressed growth and showed profound and sustained inhibition of mTOR signaling, which was recapitulated by siRNA-mediated RET knockdown. Inhibition of mTOR with INK128, a dual mTORC1 and mTORC2 kinase inhibitor, also resulted in marked growth suppression to levels similar to those seen with RET blockade. Moreover, combined treatment with AST487 and INK128 at low concentrations suppressed growth and induced apoptosis. These data establish mTOR as a key mediator of RET-mediated cell growth in thyroid cancer cells and provide a rationale for combinatorial treatments in thyroid cancers with oncogenic RET mutations.
Search for other papers by M T Barakat in
Google Scholar
PubMed
Search for other papers by K Meeran in
Google Scholar
PubMed
Search for other papers by S R Bloom in
Google Scholar
PubMed
Neuroendocrine tumours are a heterogeneous group including, for example, carcinoid, gastroenteropancreatic neuroendocrine tumours, pituitary tumours, medullary carcinoma of the thyroid and phaeochromocytomas. They have attracted much attention in recent years, both because they are relatively easy to palliate and because they have indicated the chronic effect of the particular hormone elevated. As neuroendocrine phenotypes became better understood, the definition of neuroendocrine cells changed and is now accepted as referring to cells with neurotransmitter, neuromodulator or neuropeptide hormone production, dense-core secretory granules, and the absence of axons and synapses. Neuroendocrine markers, particularly chromogranin A, are invaluable diagnostically. Study of several neuroendocrine tumours has revealed a genetic etiology, and techniques such as genetic screening have allowed risk stratification and prevention of morbidity in patients carrying the particular mutation. Pharmacological therapy for these often slow-growing tumours, e.g. with somatostatin analogues, has dramatically improved symptom control, and radiolabelled somatostatin analogues offer targeted therapy for metastatic or inoperable disease. In this review, the diagnosis and management of patients with carcinoid, gut neuroendocrine tumours, multiple endocrine neoplasia types 1 and 2, and isolated phaeochromocytoma are evaluated.
Search for other papers by Yvonne Arvidsson in
Google Scholar
PubMed
Search for other papers by Ellinor Andersson in
Google Scholar
PubMed
Search for other papers by Anders Bergström in
Google Scholar
PubMed
Search for other papers by Mattias K Andersson in
Google Scholar
PubMed
Search for other papers by Gülay Altiparmak in
Google Scholar
PubMed
Search for other papers by Ann-Christin Illerskog in
Google Scholar
PubMed
Search for other papers by Håkan Ahlman in
Google Scholar
PubMed
Lundberg Laboratory for Cancer Research, Lundberg Laboratory for Cancer Research, Department of Biochemistry, Department of Pathology
Search for other papers by Darima Lamazhapova in
Google Scholar
PubMed
Search for other papers by Ola Nilsson in
Google Scholar
PubMed
We have examined the global gene expression profile of small intestinal carcinoids by microarray analysis. High expression of a number of genes was found including amyloid precursor-like protein 1 (APLP1). Quantitative real-time PCR and western blot analysis demonstrated higher expression of APLP1 in carcinoid metastases relative to primary tumours indicating a role of APLP1 in tumour dissemination. Tissue microarray analysis of gastroentero-pancreatic tumours demonstrated a high frequency of APLP1 expression and a low frequency of APLP2 expression in neuroendocrine (NE) tumours when compared with non-NE tumours at the same sites. Meta-analysis of gene expression data from a large number of tumours outside the gastrointestinal tract confirmed a correlation between APLP1 expression and NE phenotype where high expression of APLP1 was accompanied by downregulation of APLP2 in NE tumours. Cellular localization of APLP1, APLP2 and amyloid precursor protein (APP) in carcinoid cells (GOT1) by confocal microscopy demonstrated partial co-localization with synaptophysin. This suggests that the APP family of proteins is transported to the cell membrane by synaptic microvesicles and that they may influence tumour cell adhesion and invasiveness. We conclude that APLP1 is differentially upregulated in gastrointestinal NE tumours and that APLP1 may be important for the dissemination of small intestinal carcinoids. Identification of APLP1 in NE tumours offers a novel target for treatment and may also serve as a tumour-specific marker.
Search for other papers by P D Leotlela in
Google Scholar
PubMed
Search for other papers by A Jauch in
Google Scholar
PubMed
Search for other papers by H Holtgreve-Grez in
Google Scholar
PubMed
Search for other papers by R V Thakker in
Google Scholar
PubMed
Neuroendocrine tumours (NETs) originate in tissues that contain cells derived from the embryonic neural crest, neuroectoderm and endoderm. Thus, NETs occur at many sites in the body, although the majority occur within the gastro-entero-pancreatic axis and can be subdivided into those of foregut, midgut and hindgut origin. Amongst these, only those of midgut origin are generally argentaffin positive and secrete serotonin, and hence only these should be referred to as carcinoid tumours. NETs may occur as part of complex familial endocrine cancer syndromes, such as multiple endocrine neoplasia type 1 (MEN1), although the majority occur as non-familial (i.e. sporadic) isolated tumours. Molecular genetic studies have revealed that the development of NETs may involve different genes, each of which may be associated with several different abnormalities that include point mutations, gene deletions, DNA methylation, chromosomal losses and chromosomal gains. Indeed, the foregut, midgut and hindgut NETs develop via different molecular pathways. For example, foregut NETs have frequent deletions and mutations of the MEN1 gene, whereas midgut NETs have losses of chromosome 18, 11q and 16q and hindgut NETs express transforming growth factor-alpha and the epidermal growth factor receptor. Furthermore, in lung NETs, a loss of chromosome 3p is the most frequent change and p53 mutations and chromosomal loss of 5q21 are associated with more aggressive tumours and poor survival. In addition, methylation frequencies of retinoic acid receptor-beta, E-cadherin and RAS-associated domain family genes increase with the severity of lung NETs. Thus the development and progression of NETs is associated with specific genetic abnormalities that indicate the likely involvement of different molecular pathways.
Search for other papers by Katherine I Wolf in
Google Scholar
PubMed
Search for other papers by Linda Rose-Krasnor in
Google Scholar
PubMed
Search for other papers by Stephanie Alband in
Google Scholar
PubMed
Search for other papers by Jacques W M Lenders in
Google Scholar
PubMed
Search for other papers by Lauren Fishbein in
Google Scholar
PubMed
Pheochromocytoma and paragangliomas (PPGLs) originate from the chromaffin cells of the adrenal medulla or neural crest progenitors outside the adrenal gland, respectively. The estimated annual incidence of PPGL is between 2.0 and 8.0/million adults. Minimal data exist on the impact of PPGL from the patient’s perspective. Therefore, a survey was adapted from a previously published study on gastroenteropancreatic neuroendocrine tumors to explore the voice of patients with PPGL and learn ways to improve clinical care while understanding the current gaps to direct future research. A self-reported online survey was available to patients with PPGL and those with genetic predisposition even without PPGL from June to July 2022. Survey questions captured sociodemographic and clinical characteristics, the diagnostic workup, treatment and monitoring, quality and access to care, and financial impact. Here, we report the most relevant findings on patient experience of disease burden following diagnosis. A total of 270 people responded, the majority of whom were from the USA (79%), Caucasian (88%), and female (81%). The results of this survey highlight the burden of disease on a patient’s daily life, resulting in moderate to severe financial distress, increased travel time to specialized facilities resulting in loss of work and wages, and significant delays in care. Respondents reported being unheard and unacknowledged. With a median time to diagnosis just over 2 years, the physical, mental, and emotional toll are substantial. Increasing access to PPGL specialists and centers could lead to faster diagnoses and better management, which may reduce the burden on both patients and healthcare centers.
Department of Endocrine Oncology, Department of Medical Sciences, University Hospital, Entrance 78, SE-751 85 Uppsala, Sweden
Search for other papers by Kjell Oberg in
Google Scholar
PubMed
classification and the pathology of gastro-entero-pancreatic neuroendocrine neoplasms is discussed by Prof. Günter Klöppel ( Klöppel 2011 ). A number of biomarkers has been developed during the last decades based on development of the immunoassays for various gut
Search for other papers by Vincenzo Marotta in
Google Scholar
PubMed
Search for other papers by Maria Chiara Zatelli in
Google Scholar
PubMed
Search for other papers by Concetta Sciammarella in
Google Scholar
PubMed
Search for other papers by Maria Rosaria Ambrosio in
Google Scholar
PubMed
Search for other papers by Marta Bondanelli in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by Antongiulio Faggiano in
Google Scholar
PubMed
the definition of a common marker, elevated levels of circulating CgA have been associated with almost all types of NEN, including those arising from the gastroenteropancreatic tract and the bronchopulmonary area, which represent the majority, but also
Search for other papers by G Butturini in
Google Scholar
PubMed
Search for other papers by R Bettini in
Google Scholar
PubMed
Search for other papers by E Missiaglia in
Google Scholar
PubMed
Search for other papers by W Mantovani in
Google Scholar
PubMed
Search for other papers by I Dalai in
Google Scholar
PubMed
Search for other papers by P Capelli in
Google Scholar
PubMed
Search for other papers by M Ferdeghini in
Google Scholar
PubMed
Search for other papers by P Pederzoli in
Google Scholar
PubMed
Search for other papers by A Scarpa in
Google Scholar
PubMed
Search for other papers by M Falconi in
Google Scholar
PubMed
et al. 1990 ). Several studies, including three phase-II trials ( Saltz et al. 1993 , Arnold et al. 1996 , Eriksson et al. 1997 ), reported frequent stabilization of the disease in progressive gastroenteropancreatic neuroendocrine tumours
Search for other papers by Kimberly Kamp in
Google Scholar
PubMed
Search for other papers by Ronald A M Damhuis in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
gastrointestinal (GI) tract and the pancreas, gastroenteropancreatic NETs (GEP-NETs), are considered to be relatively rare tumors. However, more recent studies on NET epidemiology have demonstrated an increasing GEP-NET incidence and prevalence over the past 30
